Impact of prior chemotherapy on outcomes with eribulin in breast cancer

A post hoc analysis of data from the pivotal EMBRACE and Study 301 trials suggests eribulin is better used sooner rather than later.
A post hoc analysis of data from the pivotal EMBRACE and Study 301 trials suggests eribulin is better used sooner rather than later.